All Eyes on Gilead’s Readout of Remdesivir for COVID-19

All Eyes on Gilead’s Readout of Remdesivir for COVID-19

Source: 
BioSpace
snippet: 

Gilead Sciences is expected to report data from a clinical trial of its antiviral drug remdesivir against COVID-19 soon. Although the data hasn’t been released yet, analysts are making predictions based on what little they do know.

With a likely vaccine a year out, optimistically, the drug, which was originally developed to treat Ebola, is considered the closest hope for a treatment. It is involved in at least five clinical trials in the U.S. and China.